OMB#: 0925 –
0625 Expiry Date:

01/31/2014


Collection of this information is authorized by The Public Health Service Act, Section 411 (42 USC 285a). Rights of your participation in the National Cancer Institute (NCI) Central Institutional Review Board (CIRB) Initiative is protected by The Privacy Act of 1974, as amended. The purpose of the information collection is to conduct reviews of clinical trial studies. Although your participation in NCI-sponsored research and completion of the forms is voluntary, if you wish to participate in the CIRB, you must complete all questions on the form. The information you provide will be combined for all participants and reported as summaries. It will be kept private to the extent provided by law.

#### NOTIFICATION TO RESPONDENT OF ESTIMATED BURDEN

Public reporting burden for this collection of information is estimated to average 10 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0625). Do not return the completed form to this address.

## Study Review Responsibility Transfer Form

Submission of this Study Review Responsibility Transfer Form indicates that the CIRB is no longer the IRB responsible for review of this study. This is a two-step process. Step 1 is to complete this form. Step 2 is to confirm the information and submit.



ncicirbcontact@emmes.com.

### **NEXT BUTTON**

If you wish to return to the Facilitated Review Submission Report, click the 'Go Back" button (all information entered will be lost). GO BACK BUTTON

# Step 2 – Confirmation and Submission

#### Step 2: Review information on this confirmation page and click "Submit" if information is correct. If

A: Once you click "Submit", your browser will automatically take you back to the Facilitated Review (FR) Submission Report webpage.

B: You will receive an email from the CIRB Operations Office confirming receipt of your transfer request.

Study Number: CALGB-80303

**Study Title:** "A Randomized Phase III Trial of Gemcitabine Plus Bevacizumab (NSC #704865 IND# 7921) versus Gemcitabine Plus Placebo in Patients with Advanced Pancreatic Cancer"

Name of IRB: Missouri Baptist Medical Center

Institution's FWA Number: FWA00001234

Local IRB Registration Number: IRB00001234

Study participants are enrolled at a site covered by this IRB.

OR

Study participants are not enrolled at a site covered by this IRB.

**IRB Approval Letter, if applicable:** C:\Documents and Settings\lcovington\Desktop\ transcript.doc OR Not applicable

After your review, select the appropriate option below:

If you want to change any information, click on "Go Back". ['Go Back' Button]

OR

If the information is correct, click the Submit button. You will receive an email acknowledgement of the submission.

['Submit' Button]

changes are required, click "Go Back" and you will be returned to the Study Review Responsibility Transfer Form where you may make changes.